Evox Therapeutics enters into agreement to advance next generation exosome-delivered AAV gene therapy for the treatment of heart disease
Evox Therapeutics Ltd, a leading exosome therapeutics company, announced a research collaboration and option agreement with the Icahn School of Medicine at Mount Sinai in New York, NY.
